0C-14-9
Trial Leaders:
Anthony El-Khoueiry
| A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies
Treatment:
Chemotherapy: Systemic
|
0C-17-1
Trial Leaders:
Anthony El-Khoueiry
| Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors
Treatment:
Other
|
0C-19-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Treatment:
(No treatments specified) |
0C-19-19
Trial Leaders:
Diana Hanna
| The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 agonist) in Combination with INCAGN01949 (an activating anti-OX40 antibody) for In Situ Intratumoral Injection for Patients with Stage IV Pancreatic and other Cancers except Melanoma
Treatment:
Immunotherapy
Vaccine
|
0C-19-20
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers
Treatment:
Immunotherapy
|
0C-19-22
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy
Treatment:
Biological Response Modifier
|
0C-20-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
|
0C-20-14
Trial Leaders:
Jorge Nieva
| Tumor-agnostic precision immunooncology and somatic targeting rational for you (TAPISTRY) Phase II Platform trial
Treatment:
Immunotherapy
|
0C-20-19
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Treatment:
Other
|
0C-21-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Treatment:
Immunotherapy
|
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-21-17
Trial Leaders:
Heinz Josef Lenz
| A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Treatment:
Other
|
0C-21-2
Trial Leaders:
Heinz Josef Lenz
| A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-21-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Treatment:
Immunotherapy
|
0C-21-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in combination with Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects with Advanced/Metastatic EGFR-Expressing Cancers
Treatment:
Other
|
0C-21-7
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients with Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Treatment:
Autologous Bone Marrow Transplant
|
0C-22-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers
Treatment:
Other
|
0S-20-8
Trial Leaders:
Gino In
| An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Treatment:
Other
Vaccine
|
2N-22-1
Trial Leaders:
Jorge Nieva
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors
Treatment:
Other
|
4B-22-3
Trial Leaders:
Anishka D'Souza
| PhI-133/NCI 10483: Phase Ib trial of Erdafitinib combined with Enfortumab Vedotin following platinum and PD1/L1 inhibitors for metastatic urothelial carcinoma with FGFR2/3 genetic alterations
Treatment:
Immunotherapy
|
CTSU-A031702
Trial Leaders:
Anishka D'Souza
| A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
SWOG-S1609
Trial Leaders:
Heinz Josef Lenz
| DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Treatment:
Immunotherapy
|
SWOG-S1931
Trial Leaders:
Varsha Tulpule
| Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Treatment:
Chemotherapy: Systemic
Immunotherapy
Surgery
|
0C-14-9
Trial Leaders:
Anthony El-Khoueiry
| A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of ceralasertib in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies
Treatment:
Chemotherapy: Systemic
|
0C-17-1
Trial Leaders:
Anthony El-Khoueiry
| Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors
Treatment:
Other
|
0C-18-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase I Study of FID-007 in Patients with Advanced Solid Tumors
Treatment:
Chemotherapy: Systemic
|
0C-18-20
Trial Leaders:
Jacob Thomas
| A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors
Treatment:
(No treatments specified) |
0C-18-21
Trial Leaders:
Diana Hanna
| A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.
Treatment:
Chemotherapy: Systemic
Immunotherapy
|
0C-19-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Treatment:
(No treatments specified) |
0C-19-10
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-19-12
Trial Leaders:
Heinz Josef Lenz
| A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL
Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and
Pancreatic Cancer Using Combination Therapy
Treatment:
Chemotherapy: Systemic
Other
|
0C-19-19
Trial Leaders:
Diana Hanna
| The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 agonist) in Combination with INCAGN01949 (an activating anti-OX40 antibody) for In Situ Intratumoral Injection for Patients with Stage IV Pancreatic and other Cancers except Melanoma
Treatment:
Immunotherapy
Vaccine
|
0C-19-20
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers
Treatment:
Immunotherapy
|
0C-19-21
Trial Leaders:
Diana Hanna
| A Phase I Study of GNX102 in patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-19-22
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy
Treatment:
Biological Response Modifier
|
0C-19-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors
Treatment:
Chemotherapy: Systemic
|
0C-19-7
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of AGEN1181, an Fc-Engineered Anti–CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with Balstilimab (AGEN2034), an Anti-PD1 Monoclonal Antibody, in Participants With Advanced Cancer
Treatment:
Immunotherapy
|
0C-19-8
Trial Leaders:
Heinz Josef Lenz
| A multicentre, open-label, non-randomised first in human study of NG-641, a tumor-selective transgene expressing adenoviral vector, in patients with metastatic or advanced epithelial tumours (STAR)
Treatment:
Immunomodulator
|
0C-20-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability,Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Treatment:
Immunotherapy
|
0C-20-10
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101)
Treatment:
Other
|
0C-20-12
Trial Leaders:
Anthony El-Khoueiry
| A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Treatment:
Other
|
0C-20-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with SelectedAdvanced Solid Tumor Malignancies
Treatment:
Other
|
0C-20-16
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
Treatment:
Other
|
0C-20-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
Treatment:
Other
|
0C-20-19
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and In Combination with Nivolumab In Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors
Treatment:
Other
|
0C-20-2
Trial Leaders:
Anthony El-Khoueiry
| Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-20-22
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/1b Study of SRF388 in Patients with Advanced Solid Tumors
Treatment:
Other
|
0C-20-23
Trial Leaders:
Anthony El-Khoueiry
| Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Treatment:
Other
|
0C-20-24
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Dose Escalation and Expansion Study of ABL503, a Bispecific Antibody of 4-1BB and PD-L1, as a Single Agent in Subjects With Any Progressive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Treatment:
Immunotherapy
|
0C-20-3
Trial Leaders:
James Hu
| A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily to Patients with Advanced Solid Tumors
Treatment:
Chemotherapy: Systemic
|
0C-20-8
Trial Leaders:
Heinz Josef Lenz
| First-In-Human Dose-Escalation Study of STP1002 in Patients with Advanced-Stage Solid Tumors
Treatment:
Other
|
0C-20-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer
Treatment:
Other
|
0C-21-1
Trial Leaders:
Anthony El-Khoueiry
| An Open Label Phase 1a/b Study Of Mtl-Cebpa In Combination With A Pd-1 Inhibitor (Pembrolizumab) In Adult Patients With Advanced Solid Tumours (Timepoint)
Treatment:
Immunotherapy
|
0C-21-10
Trial Leaders:
Anthony El-Khoueiry
| Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
Treatment:
Chemotherapy: Systemic
|
0C-21-12
Trial Leaders:
Anthony El-Khoueiry
| A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-21-13
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EGFR-expressing Cancers
Treatment:
Immunotherapy
|
0C-21-14
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozurriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-21-15
Trial Leaders:
Anthony El-Khoueiry
| Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP707 Administered Intravenously in Subjects with Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Treatment:
Chemotherapy: Systemic
|
0C-21-17
Trial Leaders:
Heinz Josef Lenz
| A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Treatment:
Other
|
0C-21-18
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study of ASP1570 in Participants with Advanced Solid Tumors
Treatment:
Immunomodulator
|
0C-21-19
Trial Leaders:
Jacob Thomas
| A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and / or NRAS Mutation Positive Solid Tumors
Treatment:
Other
|
0C-21-2
Trial Leaders:
Heinz Josef Lenz
| A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-21-20
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) in Adult Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-21-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Treatment:
Immunotherapy
|
0C-21-4
Trial Leaders:
Jacob Thomas
| A Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Pf-07257876 in Patients With Advanced or Metastatic Tumors
Treatment:
Other
|
0C-21-5
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies
Treatment:
Other
|
0C-21-6
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in combination with Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects with Advanced/Metastatic EGFR-Expressing Cancers
Treatment:
Other
|
0C-21-7
Trial Leaders:
Jacob Thomas
| A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients with Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Treatment:
Autologous Bone Marrow Transplant
|
0C-21-8
Trial Leaders:
Heinz Josef Lenz
| PhI-129 /NCI 10358: Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial)
Treatment:
Other
|
0C-21-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
Treatment:
Other
|
0C-22-1
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Study of RTX-224 for the Treatment of Patients with Advanced Solid Tumors
Treatment:
Other
|
0C-22-2
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1, Open-Label Study of the Safety, Tolerability, and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination with Approved Immune Checkpoint Inhibitors in Subjects with Relapsed/Refractory Solid Tumors
Treatment:
Immunotherapy
|
0C-22-3
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers
Treatment:
Other
|
0C-22-5
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination with a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients with Advanced Solid Tumors
Treatment:
Immunotherapy
|
0C-22-9
Trial Leaders:
Anthony El-Khoueiry
| A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose
Treatment:
Other
|
0S-12-3
Trial Leaders:
Peter Conti
| 18F-FMAU for Imaging in Cancer Patients.
Treatment:
Other
|
TEST002
Trial Leaders:
Francisco Acosta
| Test Protocol 002 Long Protocol Title112
Treatment:
Autologous Bone Marrow Transplant
Biological Response Modifier
Chemotherapy: Local
Genetic
|
0S-11-5
Trial Leaders:
Amir Goldkorn
| Circulating Tumor Cell Collection from Cancer Patients.
|
0S-12-3
Trial Leaders:
Peter Conti
| 18F-FMAU for Imaging in Cancer Patients.
|
0S-12-4
Trial Leaders:
Charite Ricker
| USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.
|
0S-15-12
Trial Leaders:
John Carpten
| Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.
|
0S-15-16
Trial Leaders:
Casey O'Connell
| Protocol for Immunology Specimen Collection from Cancer Patients, Patients with Hematologic Diagnoses, and Healthy Normal Controls
|
0S-19-4
Trial Leaders:
Jacob Thomas
| A Tissue Collection Study in Patients who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells
|
0S-20-10
Trial Leaders:
Kimberly Miller
| Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study
|
0S-21-5
Trial Leaders:
Jacob Thomas
| Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV) Antigens and Human Leucocyte Antigen (HLA) sub-Types in Patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers
|
3G-07-3
Trial Leaders:
Heinz Josef Lenz
| Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.
|
4K-03-2
Trial Leaders:
Eila Skinner
| Kidney Cancer Data and Specimen Collection Project.
|
6CNS-07-1
Trial Leaders:
Thomas Chen
| Establishment of USC CNS and Spine Tumor Bank.
|
SWOG-S2013
Trial Leaders:
Varsha Tulpule
| Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
|
